Boston Financial Mangement LLC Gilead Sciences, Inc. Transaction History

Boston Financial Mangement LLC

$3.23 Billion
Q3 2024

A detailed history of Boston Financial Mangement LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Boston Financial Mangement LLC holds 44,421 shares of GILD stock, worth $4.01 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

44,421

Previous 46,655 4.79%

Holding current value

$4.01 Million

Previous $3.2 Million 16.34%

% of portfolio

0.12%

Previous 0.1%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$66.59 - $83.99 $148,762 - $187,633	-2,234 Reduced 4.79%	44,421 $3.72 Million
Q2 2024 Jul 29, 2024	SELL	$63.15 - $72.88 $72,117 - $83,228	-1,142 Reduced 2.39%	46,655 $3.2 Million
Q1 2024 May 10, 2024	BUY	$71.58 - $87.29 $286,463 - $349,334	4,002 Added 9.14%	47,797 $3.5 Million
Q4 2023 Feb 12, 2024	SELL	$73.27 - $83.09 $11,430 - $12,962	-156 Reduced 0.35%	43,795 $3.55 Million
Q3 2023 Nov 09, 2023	SELL	$73.94 - $80.67 $266,184 - $290,412	-3,600 Reduced 7.57%	43,951 $3.29 Million
Q2 2023 Aug 07, 2023	SELL	$76.01 - $86.7 $105,577 - $120,426	-1,389 Reduced 2.84%	47,551 $3.66 Million
Q1 2023 May 12, 2023	BUY	$77.31 - $88.08 $130,963 - $149,207	1,694 Added 3.59%	48,940 $4.06 Million
Q4 2022 Jan 27, 2023	BUY	$62.32 - $89.47 $84,505 - $121,321	1,356 Added 2.95%	47,246 $0
Q3 2022 Nov 09, 2022	BUY	$59.54 - $68.01 $58,111 - $66,377	976 Added 2.17%	45,890 $2.83 Million
Q2 2022 Aug 08, 2022	BUY	$57.72 - $65.01 $73,188 - $82,432	1,268 Added 2.91%	44,914 $2.78 Million
Q1 2022 May 13, 2022	SELL	$57.92 - $72.58 $327,711 - $410,657	-5,658 Reduced 11.48%	43,646 $2.6 Million
Q4 2021 Feb 11, 2022	SELL	$64.88 - $73.64 $661,646 - $750,980	-10,198 Reduced 17.14%	49,304 $3.58 Million
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $12 Million - $12.9 Million	-177,079 Reduced 74.85%	59,502 $4.16 Million
Q2 2021 Aug 03, 2021	BUY	$63.47 - $69.35 $552,950 - $604,177	8,712 Added 3.82%	236,581 $16.3 Million
Q1 2021 May 07, 2021	BUY	$60.0 - $68.46 $1.15 Million - $1.31 Million	19,158 Added 9.18%	227,869 $14.7 Million
Q4 2020 Feb 10, 2021	SELL	$56.65 - $64.55 $3.62 Million - $4.13 Million	-63,939 Reduced 23.45%	208,711 $12.2 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $333,787 - $419,680	5,375 Added 2.01%	272,650 $17.2 Million
Q2 2020 Aug 10, 2020	BUY	$72.34 - $84.0 $917,126 - $1.06 Million	12,678 Added 4.98%	267,275 $20.6 Million
Q1 2020 May 05, 2020	BUY	$62.63 - $80.22 $3.15 Million - $4.03 Million	50,248 Added 24.59%	254,597 $19 Million
Q4 2019 Feb 05, 2020	SELL	$61.62 - $67.78 $2.27 Million - $2.5 Million	-36,884 Reduced 15.29%	204,349 $13.3 Million
Q3 2019 Nov 08, 2019	SELL	$62.51 - $69.0 $182,404 - $201,342	-2,918 Reduced 1.2%	241,233 $15.3 Million
Q2 2019 Jul 24, 2019	SELL	$61.87 - $69.38 $174,287 - $195,443	-2,817 Reduced 1.14%	244,151 $16.5 Million
Q1 2019 Apr 25, 2019	BUY	$62.53 - $70.05 $1.55 Million - $1.74 Million	24,776 Added 11.15%	246,968 $16.1 Million
Q4 2018 Jan 31, 2019	SELL	$60.54 - $79.0 $1.5 Million - $1.95 Million	-24,704 Reduced 10.01%	222,192 $13.9 Million
Q3 2018 Nov 02, 2018	BUY	$71.28 - $78.92 $3.48 Million - $3.85 Million	48,773 Added 24.62%	246,896 $19.1 Million
Q2 2018 Aug 03, 2018	SELL	$64.88 - $75.68 $310,321 - $361,977	-4,783 Reduced 2.36%	198,123 $14 Million
Q1 2018 Apr 25, 2018	SELL	$72.84 - $88.8 $260,184 - $317,193	-3,572 Reduced 1.73%	202,906 $15.3 Million
Q4 2017 Feb 05, 2018	BUY	$71.15 - $83.52 $206,335 - $242,208	2,900 Added 1.42%	206,478 $14.8 Million
Q3 2017 Oct 30, 2017	BUY	$72.11 - $85.47 $14.7 Million - $17.4 Million	203,578	203,578 $16.5 Million

Others Institutions Holding GILD

# of Institutions

1,923

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Financial Mangement LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Financial Mangement LLC with notifications on news.

Account

Boston Financial Mangement LLC Gilead Sciences, Inc. Transaction History